Proof-of-concept phase begins with first patient enrolled

Gene therapy shows sustained benefit for adults with haemophilia B

Novel inhaled ENaC blocker shows promise for treatment of cystic fibrosis

SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations

Johnson & Johnson reports phase 3 data highlighting durable outcomes and immune fitness benefits

New study to test Sema3A antibody in rare genetic kidney disease

Nipocalimab authorised for adults with antibody-positive generalised myasthenia gravis

Deucrictibant shows rapid symptom relief and strong safety profile in RAPIDe-3 study

Funding supports phase 2 study of NeuroRestore ACD856 in patients

Company highlights safety and target engagement results for VNA-318 at CTAD meeting